Drugs / anti-CD19 CAR T cell therapy
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06828042 | Jul 2025 → Dec 2027 expected | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, idiopathic inflammatory myopathy +2 | Peking University Third Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06635330 | May 2024 → Sep 2026 overdue | B-cell acute lymphoblastic leukemia | Kara Yakhteh Tajhiz Azma Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 CAR T cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06828042 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T (CAR-T) cells are a type of cancer immunotherapy treatment” NCT06635330 ↗ |
| Target | CD19 | “CAR-T cells aimed at CD19 have demonstrated promising activity in treatment of r/r B-ALL” NCT06635330 ↗ |